United Therapeutics Corp (NASDAQ:UTHR) reported better-than-expected earnings for the fourth quarter on Wednesday.
The company posted quarterly earnings of $7.70 per share which beat the analyst consensus estimate of $7.09 per share. The company reported quarterly sales of $790.200 million which missed the analyst consensus estimate of $813.077 million.
“As we close out another remarkable year with record total revenue for the fourth year in a row, I extend my thanks to our Unitherians whose unwavering commitment to innovation and excellence fuels our mission,” said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. “Looking ahead, our ADVANCE OUTCOMES and TETON-1 clinical programs are on the cusp of unveiling pivotal data that could unlock significant new treatment options for patients, launching a period of transformational growth for UT.”
United Therapeutics shares fell 5.6% to trade at $505.28 on Thursday.
These analysts made changes to their price targets on United Therapeutics following earnings announcement.
- Wells Fargo analyst Benjamin Burnett maintained United Therapeutics with an Equal-Weight rating and raised the price target from $423 to $466.
- RBC Capital analyst Lisa Walter maintained the stock with an Outperform rating and raised the price target from $587 to $643.
- Oppenheimer analyst Andreas Argyrides maintained United Therapeutics with an Outperform rating and raised the price target from $575 to $600.
- TD Cowen analyst Joseph Thome maintained the stock with a Buy and raised the price target from $525 to $575.
- HC Wainwright & Co. analyst Andrew S. Fein maintained United Therapeutics with a Buy and raised the price target from $525 to $600.
Considering buying UTHR stock? Here’s what analysts think:
Photo via Shutterstock